Claims
- 1. A compound having the formula (4):
- 2. The compound of claim 1 wherein R1 and R2 are both H, Z is —C—C—, Z1 is zero, Z2 is CH2 and n is O.
- 3. The compound of claim 2 wherein R5 is H , R6 is CH3, and R7 is CH3.
- 4. The compound of claim 2 wherein R5 is CH3, R6 is CH3 and R7 is CH3.
- 5. The compound of claim 2 wherein R5 is OCH3, R6 is CH3, and R7 is CH3.
- 6. The compound of claim 2 wherein R5 is OH, R6 is CH3 and R7 is CH3.
- 7. The compound of claim 2 wherein R5 is H and R6 and R7 are together —(CH2)4—.
- 8. The compound of claim 2 wherein R5 is CH3 and R6 and R7 are together —(CH2)4—.
- 9. The compound of claim 2 wherein R5 is OCH3 and R6 and R7 are together —(CH2)4—.
- 10. The compound of claim 2 wherein R5 is OH and R6 and R7 are together —(CH2)4—.
- 11. A method for treating a patient having an estrogen dependent illness comprising administering to said patient an effective amount of a compound having the following formula (4):
- 12. The method of claim 11, wherein said compound is incorporated into a suitable pharmaceutical carrier.
- 13. The method of claim 12, wherein said suitably pharmaceutical carrier is physiologic saline, 5 percent dextrose.
- 14. The method of claim 11, wherein said treatment is selected from therapeutic treatment and prophylactic treatment.
- 15. The method of claim 11, wherein said administration is parenteral.
- 16. The method of claim 11, wherein said administration is oral.
- 17. The method of claim 11, wherein R1 and R2 are both H, Z is —C—C—, Z1 is zero, Z2 is CH2 and n is O.
- 18. The method of claim 17, wherein R6 and R7 are both CH3 and R5 is selected from the group H, CH3, OCH3 and OH.
- 19. The method of claim 17, wherein R6 and R7 are together —(CH2)4— and R5 is selected from the group H, CH3, OCH3 and OH.
- 20. The compound of claim 1, wherein R1 and R2 are hydrogen, Z is S, Z1 is C═O, Z2 is O, m is 1, R6 and R7 are together (CH2)q and q is 6, wherein q is 6 and R5 is selected from the group 4—OSO2NH2, H, 2—CH3, and 4—F.
- 21. The method of claim 11, wherein R1 and R2 are hydrogen, Z is S, Z is C═O, Z2 is O, m is 1, R6 and R7 are together (CH2)q and q is 6, wherein q is 6 and R5 is selected from the group 4—OSO2NH2, H, 2—CH3, and 4—F.
CROSS REFERENCE TO RELATED APPLICATION
[0001] The present application is a continuation-in-part of U.S. patent application Ser. No. 09/164,889, filed Oct. 1, 1998 for “Compounds for the Treatment of Estrogen-Dependent Illnesses and Methods for Making and Using the Same”, the contents of which are hereby incorporated by reference.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09845850 |
Apr 2001 |
US |
Child |
10174092 |
Jun 2002 |
US |
Parent |
09536331 |
Mar 2000 |
US |
Child |
09845850 |
Apr 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09164889 |
Oct 1998 |
US |
Child |
09536331 |
Mar 2000 |
US |